- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-19-0027317

About Aspira Pathlab & Diagnostics Limited
Data last updated:
Aspira Pathlab & Diagnostics Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the diagnostic centers and pathology labs segment of the healthcare sector. It was incorporated on 03 July 1973 and has been in existence for over 53 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L85100MH1973PLC289209. Its GSTIN is 27AAACU3049G1ZF (Maharashtra). It is a listed company as per MCA records. Its shares are listed on BSE: 540788.
The company has an authorised share capital of ₹35 Cr and a paid-up capital of ₹15.79 Cr. It was formerly known as Utkal Soap Products Ltd and Industrial Gas & Steel Products (India) Limited. It is led by directors including Pankaj Jashwant Shah (Managing Director) and Manas Rajendra Mengar.
Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹24.98 Cr, a growth of 13.5% compared to the previous year. For the same year it recorded a net profit of ₹5 Lakh (net margin 0.2%) and EBITDA of ₹1.46 Cr (EBITDA margin 5.8%). The net worth stands at ₹13.58 Cr (up 1.2% YoY). Total assets are valued at ₹16.27 Cr (up 1.9% YoY).
The company has about 62 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Aspira Diagnostics. As per MCA filings, the company has satisfied charges of ₹6.22 Cr on record. Court records list 5 cases involving the company, including 3 filed by the company and 2 filed against it; 1 case is pending. The company has 3 deals on record (3 market trades); the latest was in July 2018.
Aspira Pathlab & Diagnostics Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0027317). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aspiradiagnostics.com.
Company details
Name history
Aspira Pathlab & Diagnostics has undergone 3 name changes throughout its history. The company was previously known as Utkal Soap Products Ltd, Industrial Gas & Steel Products (India) Limited, and Utkal Soap Products Limited. The current legal name is Aspira Pathlab & Diagnostics Limited.
| Company Name | Status |
|---|---|
| Aspira Pathlab & Diagnostics Limited | Current |
| Utkal Soap Products Ltd | Previous |
| Industrial Gas & Steel Products (India) Limited | Previous |
| Utkal Soap Products Limited | Previous |
CIN history
Aspira Pathlab & Diagnostics has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L85100MH1973PLC289209, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L85100MH1973PLC289209 | Current |
| L51909WB1973PLC028878 | Previous |
| L85100WB1973PLC028878 | Previous |
Recognitions & Rankings of Aspira Pathlab & Diagnostics
Contact details
Aspira Pathlab & Diagnostics Limited's registered office is in Mumbai, Maharashtra. Its website is aspiradiagnostics.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Apps
- Registered AddressFlat No.2 R.D. Shah Bldg Shraddhanand Road Opp. Ghatkopar Railway Station Ghatkopa, R (West), Mumbai, Maharashtra, India – 400086
- IndustryHealthcare, Diagnostic Centers & Pathology Labs
To see the full contact details of Aspira Pathlab & Diagnostics Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Aspira Pathlab & Diagnostics operates one associated brand: Aspira Diagnostics. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pathology lab services are operated through a chain of facilities. | aspiradiagnostics.com |
Business activity
The main business activity of Aspira Pathlab & Diagnostics is hospital and medical care. In detail, this covers medical and dental practice, nursing, pathology, blood bank services, etc..
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q2 | Medical and dental practice, Nursing, pathology, blood bank services, etc. |
To see the full business activity and turnover split of Aspira Pathlab & Diagnostics Limited, buy the company report.
Financials of Aspira Pathlab & Diagnostics Limited
FY 2025-26 filings availableAspira Pathlab & Diagnostics Limited reported revenue of ₹24.98 Cr (up 13.5% YoY) for FY 2025-26.
Financial Highlights
FY 2024-25 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Income statement | ||
| Revenue | 22.00 | 13.20 |
| Revenue growth | +66.7% | - |
| EBITDA | 3.47 | (1.20) |
| EBITDA margin | +15.8% | -9.1% |
| Profit before tax | 2.02 | (2.69) |
| Net profit | 2.05 | (2.69) |
| Net profit margin | +9.3% | -20.4% |
| EPS (₹) | 1.97 | (2.60) |
| Balance sheet | ||
| Total assets | 15.92 | 13.34 |
| Net worth | 13.37 | 11.22 |
| Total debt | 1.99 | 1.70 |
| Cash & bank | 2.14 | 1.38 |
| Net working capital | 3.81 | 2.98 |
| Cash flow | ||
| Cash from operations | 1.83 | 1.05 |
| Cash from investing | 0.12 | 0.14 |
| Cash from financing | (0.99) | (0.95) |
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Jun 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.25 | 5.78 | 5.41 | 6.18 | 4.64 | 3.82 | 2.60 |
| Revenue growth (YoY) | +13.2% | +51.3% | - | - | +78.5% | - | - |
| Other income | 0.11 | 0.13 | 0.09 | 0.08 | 0.16 | 0.08 | 0.10 |
| EBITDA | 0.68 | 0.92 | 0.61 | 1.28 | 0.27 | (0.20) | (0.43) |
| EBITDA margin | +13.0% | +15.9% | +11.3% | +20.7% | +5.8% | -5.2% | -16.5% |
| Depreciation | 0.37 | 0.37 | 0.39 | 0.36 | 0.38 | 0.38 | 0.39 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.42 | 0.68 | 0.31 | 1.00 | 0.05 | (0.50) | (0.72) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | 0.42 | 0.68 | 0.31 | 1.00 | 0.05 | (0.50) | (0.72) |
| EPS (₹) | 0.41 | 0.66 | 0.30 | 0.96 | 0.05 | (0.49) | (0.70) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 24.98 | 22.00 | 13.20 | 14.46 | 19.54 | 15.21 | 8.42 |
| Revenue growth | +13.6% | +66.7% | -8.7% | -26.0% | +28.5% | +80.6% | - |
| EBITDA | 1.46 | 3.52 | (1.20) | 1.60 | 6.37 | 3.52 | (1.84) |
| EBITDA margin | +5.8% | +16.0% | -9.1% | +11.1% | +32.6% | +23.1% | -21.9% |
| Profit before tax | 0.05 | 2.07 | (2.69) | (0.09) | 4.45 | 1.39 | (4.22) |
| Net profit | 0.05 | 2.10 | (2.69) | (0.09) | 4.45 | 1.39 | (4.25) |
| Net profit margin | +0.2% | +9.6% | -20.4% | -0.6% | +22.8% | +9.1% | -50.5% |
| EPS (₹) | 0.05 | 2.01 | (2.60) | (0.09) | 4.33 | 1.34 | (4.56) |
| Balance sheet | |||||||
| Total assets | 16.27 | 15.97 | 13.34 | 16.43 | 16.99 | 10.60 | 12.90 |
| Net worth | 13.58 | 13.42 | 11.22 | 13.71 | 13.65 | 9.08 | 4.49 |
| Total debt | 1.97 | 1.99 | 1.70 | 2.35 | 3.06 | 1.31 | 8.19 |
| Cash & bank | 1.68 | 2.14 | 1.38 | 2.35 | 1.64 | 1.19 | 1.10 |
| Net working capital | 2.35 | 3.81 | 2.98 | 4.95 | 5.99 | 2.70 | 1.85 |
| Cash flow | |||||||
| Cash from operations | 1.45 | 1.88 | 1.05 | (0.01) | 2.03 | 5.67 | (1.87) |
| Cash from investing | (0.80) | 0.07 | 0.14 | 0.16 | (0.51) | (0.09) | 0.24 |
| Cash from financing | (1.14) | (0.99) | (0.95) | (0.94) | (1.35) | (2.17) | 1.27 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.26 | 6.17 | 6.52 | 5.12 | 8.09 | 5.25 | 5.78 | 5.41 |
| Revenue growth (YoY) | -22.6% | +17.5% | +12.8% | -5.4% | +30.9% | +13.2% | - | - |
| Other income | 0.09 | 0.12 | 0.14 | 0.13 | 0.14 | 0.11 | 0.13 | 0.09 |
| Total expenses | 6.94 | 5.83 | 6.86 | 6.33 | 5.90 | 4.43 | 4.72 | 4.64 |
| EBITDA | (0.68) | 0.34 | (0.34) | (1.21) | 2.19 | 0.82 | 1.06 | 0.77 |
| EBITDA margin | -10.9% | +5.5% | -5.2% | -23.6% | +27.1% | +15.6% | +18.3% | +14.2% |
| Depreciation | 0.46 | 0.41 | 0.40 | 0.38 | 0.40 | 0.37 | 0.37 | 0.39 |
| Interest | 0.11 | 0.09 | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 | 0.09 |
| Profit before tax | (1.16) | (0.04) | (0.70) | (1.56) | 1.83 | 0.47 | 0.73 | 0.38 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Jun 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.25 | 5.78 | 5.41 | 6.18 | 4.64 | 3.82 | 2.60 |
| Revenue growth (YoY) | +13.2% | +51.3% | - | - | +78.5% | - | - |
| Other income | 0.11 | 0.13 | 0.09 | 0.08 | 0.16 | 0.08 | 0.10 |
| EBITDA | 0.68 | 0.92 | 0.61 | 1.28 | 0.27 | (0.20) | (0.43) |
| EBITDA margin | +13.0% | +15.9% | +11.3% | +20.7% | +5.8% | -5.2% | -16.5% |
| Depreciation | 0.37 | 0.37 | 0.39 | 0.36 | 0.38 | 0.38 | 0.39 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.42 | 0.68 | 0.31 | 1.00 | 0.05 | (0.50) | (0.72) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | 0.42 | 0.68 | 0.31 | 1.00 | 0.05 | (0.50) | (0.72) |
| EPS (₹) | 0.41 | 0.66 | 0.30 | 0.96 | 0.05 | (0.49) | (0.70) |
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Revenue | 22.00 | 13.20 |
| Revenue growth | +66.7% | - |
| Other income | 0.39 | 0.42 |
| Total expenses | 18.53 | 14.40 |
| Employee cost | 7.33 | 6.20 |
| EBITDA | 3.47 | (1.20) |
| EBITDA margin | +15.8% | -9.1% |
| Depreciation | 1.49 | 1.54 |
| Interest | 0.35 | 0.37 |
| Profit before tax | 2.02 | (2.69) |
| Tax | 0.00 | 0.00 |
| Net profit | 2.05 | (2.69) |
| Net profit margin | +9.3% | -20.4% |
| EPS (₹) | 1.97 | (2.60) |
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | 16.43 | 16.30 |
| Reserves & surplus | (3.06) | (5.08) |
| Shareholders' funds (net worth) | 13.37 | 11.22 |
| Minority interest | 0.00 | 0.00 |
| Secured loans | 0.00 | 0.00 |
| Unsecured loans | 1.99 | 1.70 |
| Total debt | 1.99 | 1.70 |
| Total liabilities | 15.92 | 13.34 |
| Assets | ||
| Gross block | 18.31 | 17.20 |
| Net block | 6.53 | 6.79 |
| Capital work in progress | 0.00 | 0.00 |
| Investments | 0.08 | 0.00 |
| Inventories | 0.51 | 0.45 |
| Sundry debtors | 2.35 | 2.24 |
| Cash & bank balances | 2.14 | 1.38 |
| Loans & advances | 0.36 | 0.28 |
| Total current assets | 5.36 | 4.35 |
| Total current liabilities | 1.55 | 1.37 |
| Net working capital | 3.81 | 2.98 |
| Total assets | 15.92 | 13.34 |
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Opening cash | 0.80 | 0.57 |
| Net cash from operating activities | 1.83 | 1.05 |
| Net cash from investing activities | 0.12 | 0.14 |
| Net cash from financing activities | (0.99) | (0.95) |
| Net change in cash | 0.95 | 0.24 |
| Closing cash | 2.14 | 1.38 |
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Growth | ||
| Sales growth | +66.7% | - |
| EBITDA growth | +389.2% | - |
| PBT growth | +9998.0% | +9997.0% |
| Net income growth | +176.2% | - |
| Profitability & leverage | ||
| Net income margin | +9.2% | -20.4% |
| Return on capital employed | +11.5% | 0.0% |
| Return on net worth | +16.5% | 0.0% |
| Debt / equity | 0.15 | 0.15 |
| Long-term debt / equity | 0.09 | 0.09 |
| Interest cover | 17.68 | -13.50 |
| Efficiency & per share | ||
| Fixed asset turnover | 1.24 | 0.77 |
| Inventory turnover | 45.83 | 29.33 |
| Debtors turnover | 9.59 | 5.89 |
| EPS (₹) | 1.97 | (2.60) |
| Dividend per share (₹) | 0.00 | 0.00 |
| Book value per share (₹) | 7.03 | 5.07 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.26 | 6.17 | 6.52 | 5.12 | 8.09 | 5.25 | 5.78 | 5.41 |
| Revenue growth (YoY) | -22.6% | +17.5% | +12.8% | -5.4% | +30.9% | +13.2% | - | - |
| Other income | 0.09 | 0.12 | 0.14 | 0.13 | 0.14 | 0.11 | 0.13 | 0.09 |
| Total expenses | 6.94 | 5.83 | 6.86 | 6.33 | 5.90 | 4.43 | 4.72 | 4.64 |
| EBITDA | (0.68) | 0.34 | (0.34) | (1.21) | 2.19 | 0.82 | 1.06 | 0.77 |
| EBITDA margin | -10.9% | +5.5% | -5.2% | -23.6% | +27.1% | +15.6% | +18.3% | +14.2% |
| Depreciation | 0.46 | 0.41 | 0.40 | 0.38 | 0.40 | 0.37 | 0.37 | 0.39 |
| Interest | 0.11 | 0.09 | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 | 0.09 |
| Profit before tax | (1.16) | (0.04) | (0.70) | (1.56) | 1.83 | 0.47 | 0.73 | 0.38 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 24.98 | 22.00 | 13.20 | 14.46 | 19.54 | 15.21 | 8.42 |
| Revenue growth | +13.6% | +66.7% | -8.7% | -26.0% | +28.5% | +80.6% | - |
| Other income | 0.52 | 0.39 | 0.42 | 0.32 | 0.09 | 0.20 | 0.29 |
| Total expenses | 23.52 | 18.48 | 14.40 | 12.86 | 13.17 | 11.69 | 10.26 |
| Employee cost | 0.00 | 7.33 | 6.20 | 5.59 | 5.02 | 4.03 | 4.95 |
| EBITDA | 1.46 | 3.52 | (1.20) | 1.60 | 6.37 | 3.52 | (1.84) |
| EBITDA margin | +5.8% | +16.0% | -9.1% | +11.1% | +32.6% | +23.1% | -21.9% |
| Depreciation | 1.54 | 1.49 | 1.54 | 1.59 | 1.64 | 1.44 | 1.66 |
| Interest | 0.39 | 0.35 | 0.37 | 0.42 | 0.37 | 0.89 | 1.01 |
| Profit before tax | 0.05 | 2.07 | (2.69) | (0.09) | 4.45 | 1.39 | (4.22) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Net profit | 0.05 | 2.10 | (2.69) | (0.09) | 4.45 | 1.39 | (4.25) |
| Net profit margin | +0.2% | +9.6% | -20.4% | -0.6% | +22.8% | +9.1% | -50.5% |
| EPS (₹) | 0.05 | 2.01 | (2.60) | (0.09) | 4.33 | 1.34 | (4.56) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 16.57 | 16.43 | 16.30 | 16.18 | 16.08 | 15.99 | 14.91 |
| Reserves & surplus | (2.99) | (3.01) | (5.08) | (2.47) | (2.43) | (6.91) | (10.42) |
| Shareholders' funds (net worth) | 13.58 | 13.42 | 11.22 | 13.71 | 13.65 | 9.08 | 4.49 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 | 4.91 |
| Unsecured loans | 1.97 | 1.99 | 1.70 | 2.35 | 3.06 | 0.83 | 3.28 |
| Total debt | 1.97 | 1.99 | 1.70 | 2.35 | 3.06 | 1.31 | 8.19 |
| Total liabilities | 16.27 | 15.97 | 13.34 | 16.43 | 16.99 | 10.60 | 12.90 |
| Assets | |||||||
| Gross block | 20.54 | 18.31 | 17.20 | 16.88 | 16.87 | 13.41 | 12.91 |
| Net block | 7.21 | 6.53 | 6.79 | 8.00 | 9.58 | 7.75 | 8.70 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.70 | 0.51 | 0.45 | 0.40 | 0.40 | 0.37 | 0.28 |
| Sundry debtors | 1.73 | 2.35 | 2.24 | 2.34 | 4.49 | 1.70 | 0.60 |
| Cash & bank balances | 1.68 | 2.14 | 1.38 | 2.35 | 1.64 | 1.19 | 1.10 |
| Loans & advances | 0.47 | 0.36 | 0.28 | 0.77 | 0.60 | 0.62 | 1.31 |
| Total current assets | 4.58 | 5.36 | 4.35 | 5.86 | 7.13 | 3.88 | 3.29 |
| Total current liabilities | 2.23 | 1.55 | 1.37 | 0.91 | 1.14 | 1.18 | 1.44 |
| Net working capital | 2.35 | 3.81 | 2.98 | 4.95 | 5.99 | 2.70 | 1.85 |
| Total assets | 16.27 | 15.97 | 13.34 | 16.43 | 16.99 | 10.60 | 12.90 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.75 | 0.80 | 0.57 | 1.35 | 1.19 | (2.22) | (1.87) |
| Net cash from operating activities | 1.45 | 1.88 | 1.05 | (0.01) | 2.03 | 5.67 | (1.87) |
| Net cash from investing activities | (0.80) | 0.07 | 0.14 | 0.16 | (0.51) | (0.09) | 0.24 |
| Net cash from financing activities | (1.14) | (0.99) | (0.95) | (0.94) | (1.35) | (2.17) | 1.27 |
| Net change in cash | (0.49) | 0.95 | 0.24 | (0.79) | 0.17 | 3.41 | (0.35) |
| Closing cash | 1.68 | 2.14 | 1.38 | 2.35 | 1.64 | 1.19 | 1.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +13.6% | +66.7% | -8.7% | -26.0% | +28.5% | +80.6% | - |
| EBITDA growth | -58.5% | +393.3% | -175.0% | -74.9% | +81.0% | +291.3% | - |
| PBT growth | -97.6% | +9998.0% | -2888.9% | - | +220.1% | +9998.0% | +18.5% |
| Net income growth | -97.6% | +178.1% | -2888.9% | -102.0% | +220.1% | +132.7% | - |
| Revenue CAGR (3Y) | +20.0% | +4.0% | -4.6% | +19.8% | +36.8% | +51.7% | +122.9% |
| EBITDA CAGR (3Y) | -3.0% | -17.9% | - | - | - | - | -10.5% |
| Profitability & leverage | |||||||
| Net income margin | +0.2% | +9.4% | -20.4% | -0.6% | +22.8% | +9.1% | -50.5% |
| Return on capital employed | +1.6% | +11.7% | 0.0% | 0.0% | +17.6% | +11.5% | 0.0% |
| Return on net worth | +0.3% | +16.9% | 0.0% | 0.0% | +23.1% | +15.2% | 0.0% |
| Debt / equity | 0.15 | 0.15 | 0.16 | 0.20 | 0.19 | 0.70 | 1.47 |
| Long-term debt / equity | 0.08 | 0.09 | 0.11 | 0.15 | 0.13 | 0.37 | 0.84 |
| Interest cover | -487.50 | 17.24 | -13.50 | 4,200.00 | 7.82 | 42.79 | -28.86 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.29 | 1.24 | 0.77 | 0.86 | 1.29 | 1.16 | 0.69 |
| Inventory turnover | 41.29 | 45.83 | 31.06 | 36.15 | 50.75 | 46.80 | 30.07 |
| Debtors turnover | 12.25 | 9.59 | 5.76 | 4.23 | 6.31 | 13.23 | 12.03 |
| EPS (₹) | 0.05 | 2.01 | (2.60) | (0.09) | 4.33 | 1.34 | (4.56) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 7.09 | 7.08 | 5.07 | 7.60 | 7.64 | 3.29 | (1.21) |
To see the full year-wise statements and ratios of Aspira Pathlab & Diagnostics Limited, buy the company report.
Board of directors of Aspira Pathlab & Diagnostics Limited
Aspira Pathlab & Diagnostics has 7 current directors and 25 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manas Rajendra Mengar | Director | 12 Aug 2023 | 3 Years 3 Months | Current |
| Vaibhav Odhekar Also directs: Omizoo Private Limited, Jivi Care Private Limited | Additional Director | 23 May 2026 | 0 Years 5 Months | Current |
| Kiran Raghavendra Awasthi Also directs: Raj Oil Mills Limited | Director | 12 Nov 2025 | 1 Years 0 Months | Current |
| Nikunj Velji Mange Also directs: Growfresh Agro Venture LLP, Ybl Properties LLP | Director | 29 Aug 2020 | 6 Years 2 Months | Current |
| Haseeb Ahmad Drabu Also directs: Essar Power Limited, Essar Ports & Logistics Limited, Salaya Bulk Terminals Limited and 5 more | Director | 27 Oct 2018 | 8 Years 0 Months | Current |
| Pankaj Jashwant Shah Also directs: Aspira Dna Diagnostics Gujarat LLP | Managing Director | 01 Aug 2016 | 10 Years 3 Months | Current |
Auditor
Aspira Pathlab & Diagnostics Limited is audited by P Khetan & Co. for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| P Khetan & Co. | FY 2024 | 327386E |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 18.40%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 81.60%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 18.40% | 18.40% | 18.40% | 18.40% |
| Public | 81.60% | 81.60% | 81.60% | 81.60% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 19 Jul 2020 | 100359435 | Hdfc Bank Limited | ₹96.8 Lakh | Satisfied | |
| 04 Jun 2018 | 100186823 | Hdfc Bank Limited | ₹50 Lakh | Satisfied | |
| 07 Dec 2016 | 100077364 | Hdfc Bank Limited | ₹4.75 Cr | Satisfied |
To see the full charge records of Aspira Pathlab & Diagnostics Limited, buy the company report.
Total charge records: 3 View all charges
Deals & funding
Aspira Pathlab & Diagnostics Limited has 3 deals on record (3 market trades); the latest was in July 2018.
Deals on record (3 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2018 | Market trade | ₹5.3 Lakh | Seller: an individual |
| Apr 2018 | Market trade | ₹18.4 Lakh | Buyer: 2 individuals Seller: 2 individuals |
| Feb 2018 | Market trade | ₹4.2 Lakh | Buyer: an individual Seller: an individual |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Aspira Pathlab & Diagnostics Limited has 5 court cases on record: 3 filed by Aspira Pathlab & Diagnostics, 2 filed against it. 1 case is pending and 4 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 3 | 2 | 1 |
| District courts | 2 | 0 | 0 |
Cases on record (5 of 5)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai City Civil Court, Maharashtra | Commercial matter | Filed by the company against Apollo Health and Lifestyle Limited | Disposed |
| Bombay High Court | Interim or miscellaneous application | Filed by the company against Municipal Corporation of Greater Mumbai and 7 Ors | Pending |
| District court, Calcutta, West Bengal | Civil suit | Filed by the company against Ms Indage Vinters Ltd and 4 others | Disposed |
| High Court | Writ petition | Filed against the company by an individual | Disposed |
| High Court | Court case (ITP) | Filed against the company by an individual | Disposed |
To see the full case history of Aspira Pathlab & Diagnostics Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Aspira Pathlab & Diagnostics Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Aspira Pathlab & Diagnostics Limited has a workforce of 62 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 62 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Aspira Pathlab & Diagnostics Limited, buy the company report.
GST
Aspira Pathlab & Diagnostics has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACU3049G1ZF | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Aspira Pathlab & Diagnostics Limited, buy the company report.
Recent activity
Aspira Pathlab & Diagnostics Limited has 25 board changes on record since 2010: 7 appointments and 18 cessations. The latest: Vaibhav Odhekar was appointed as Additional Director on 23 May 2026.
22 earlier events are in the company report.
News
Frequently asked questions
Aspira Pathlab & Diagnostics is an active public limited company based in Mumbai, Maharashtra, India. The company works in diagnostic centers and pathology labs, within the healthcare industry. It was incorporated on 03 July 1973 (53+ years old) and is registered under CIN L85100MH1973PLC289209. Listed on BSE: 540788.
Aspira Pathlab & Diagnostics reported revenue of ₹24.98 Cr for FY 2025-26 (up 13.5% YoY) based on standalone financials.
Aspira Pathlab & Diagnostics has 7 current directors:
- Pankaj Jashwant Shah - Managing Director
- Manas Rajendra Mengar - Director
- Vaibhav Odhekar - Additional Director
- Kiran Raghavendra Awasthi - Director
- Nikunj Velji Mange - Director
- Haseeb Ahmad Drabu - Director
- Avinash Chander Mahajan - Director
The latest financial statements of Aspira Pathlab & Diagnostics on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 26 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Aspira Pathlab & Diagnostics is 27AAACU3049G1ZF, registered in Maharashtra.
The CIN (Corporate Identification Number) of Aspira Pathlab & Diagnostics is L85100MH1973PLC289209. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Aspira Pathlab & Diagnostics is a listed company as per MCA records. Its shares are listed on BSE (code: 540788).
Aspira Pathlab & Diagnostics has 5 court cases on record: 3 filed by the company and 2 filed against it. 1 is pending. Most are in the high courts.
Aspira Pathlab & Diagnostics was incorporated on 03 July 1973, making it 53+ years old. It is registered with the Registrar of Companies, Mumbai.
Aspira Pathlab & Diagnostics has 3 deals on record (3 market trades); the latest was in July 2018.

